Cristiane Gomes-Lima

Dr. Cristiane Gomes-Lima

University of Brasilia (UnB)
+1

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
Cristiane Gomes-LimaCristiane Gomes-Lima
Cristiane Gomes-Lima
DWDi Wu
Di Wu
SRSarika N Rao
Sarika N Rao
SPSree Punukollu
Sree Punukollu
RHRama Hritani
Rama Hritani
KBKenneth Burman
Kenneth Burman
Background and Objective: The brain is an unusual site for distant metastases of differentiated thyroid carcinoma (DTC). The aim of this study was to document the prevalence of brain metastases from DTC at our institutions and to analyze the current therapies and the outcomes of these patients. Methods: We performed a retrospective chart review of patients with DTC and secondary neoplasia of the brain. Results: From 2002 to 2016, 9514 cases of thyroid cancer were evaluated across our institutions and 24 patients met our inclusion criteria, corresponding to a prevalence of 0.3% of patients with DTC. Fourteen (58.3%) were female and 10 (41.7%) were male. Fifteen patients had papillary thyroid cancer (PTC) (62.5%). Brain metastases were diagnosed 0 to 37 years (mean ± SD, 10.6 ± 10.4 years) after the initial diagnosis of thyroid cancer. Patients undergoing surgery had a median survival time longer than those that did not undergo surgery (27.3 months vs 6.8 months; P = 0.15). Patients who underwent stereotactic radiosurgery (SRS) had a median survival time longer than those that did not receive SRS (52.5 months vs 6.7 months; P = 0.11). Twelve patients (50%) were treated with tyrosine kinase inhibitors (TKIs), and they had a better survival than those who have not used a TKI (median survival time, 27.2 months vs 4.7 months; P < 0.05). Conclusion: The prevalence of brain metastases of DTC in our institutions was 0.3% over 15 years. The median survival time after diagnosis of brain metastases was 19 months. In our study population, the use of TKI improved the survival rates.

2 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KJKirk Jensen
Kirk Jensen
STShilpa Thakur
Shilpa Thakur
APAneeta Patel
Aneeta Patel
MTMaria Cecilia Mendonca Torres
Maria Cecilia Mendonca Torres
JCJohn Costello
John Costello
JKJOANNA KLUBO-GWIEZDZINSKA
JOANNA KLUBO-GWIEZDZINSKA
The detection of rare mutational targets in plasma (liquid biopsy) has emerged as a promising tool for the assessment of patients with cancer. We determined the presence of cell-free DNA containing the BRAFV600E mutations (cfBRAFV600E) in plasma samples from 57 patients with papillary thyroid cancer (PTC) with somatic BRAFV600E mutation-positive primary tumors using microfluidic digital PCR, and co-amplification at lower denaturation temperature (COLD) PCR. Mutant cfBRAFV600E alleles were detected in 24/57 (42.1%) of the examined patients. The presence of cfBRAFV600E was significantly associated with tumor size (p = 0.03), multifocal patterns of growth (p = 0.03), the presence of extrathyroidal gross extension (p = 0.02) and the presence of pulmonary micrometastases (p = 0.04). In patients with low-, intermediate- and high-risk PTCs, cfBRAFV600E was detected in 4/19 (21.0%), 8/22 (36.3%) and 12/16 (75.0%) of cases, respectively. Patients with detectable cfBRAFV600E were characterized by a 4.68 times higher likelihood of non-excellent response to therapy, as compared to patients without detectable cfBRAFV600E (OR (odds ratios), 4.68; 95% CI (confidence intervals)) 1.26–17.32; p = 0.02). In summary, the combination of digital polymerase chain reaction (dPCR) with COLD-PCR enables the detection of BRAFV600E in the liquid biopsy from patients with PTCs and could prove useful for the identification of patients with PTC at an increased risk for a structurally or biochemically incomplete or indeterminate response to treatment.

2 March 2022 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
Cristiane Gomes-LimaCristiane Gomes-Lima
Cristiane Gomes-Lima
SCSanjita Chittimoju
Sanjita Chittimoju
LWLeen Wehbeh
Leen Wehbeh
SDSunita Dia
Sunita Dia
PPPrathyusha Pagadala
Prathyusha Pagadala
KBKenneth Burman
Kenneth Burman
Context Recombinant human thyrotropin (rhTSH) is currently not Food and Drug Administration approved for the treatment of high-risk patients with differentiated thyroid cancer (DTC). Objective The goal of our study was to compare the outcomes in higher-risk patients with metastatic DTC prepared for radioiodine (RAI) therapy with rhTSH vs thyroid hormone withdrawal (THW). Methods A retrospective chart review was performed of patients with metastatic DTC in follow-up at MedStar Washington Hospital Center and MedStar Georgetown University Hospital from 2009 to 2017. Patients were divided according to their preparation for RAI therapy, with assessment of progression-free survival (PFS) and overall survival (OS). Results Fifty-five patients with distant metastases (16 men, 39 women) were prepared for RAI therapy exclusively either with rhTSH (n = 27) or with THW (n = 28). There were no statistically significant differences between the groups regarding clinicopathological features and history of RAI therapies. The median follow-up time for patients with rhTSH-aided therapies was 4.2 years (range, 3.3-5.5 years) and for patients with THW-aided therapies was 6.8 years (range, 4.2-11.6 years) (P = .002). Multivariate analysis showed that the method of thyrotropin stimulation was not associated with a difference in PFS or OS. Conclusion As has been shown previously for low-risk DTC, this study indicates that the mode of preparation for RAI therapy does not appear to influence the outcomes of patients with metastatic DTC. PFS and OS were similar for patients with THW-aided or rhTSH-aided RAI therapies.

11 September 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
Cristiane Gomes-LimaCristiane Gomes-Lima
Cristiane Gomes-Lima
WZWen Zhou
Wen Zhou
ZQZoe Quandt
Zoe Quandt
Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?

1 March 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MPM. Peravali
M. Peravali
Cristiane Gomes-LimaCristiane Gomes-Lima
Cristiane Gomes-Lima
ETE. Tefera
E. Tefera
MBM. Baker
M. Baker
MSM. Sherchan
M. Sherchan
IVI. Veytsman
I. Veytsman

6 January 2023 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
Cristiane Gomes-LimaCristiane Gomes-Lima
Cristiane Gomes-Lima
SCSanjita Chittimoju
Sanjita Chittimoju
LWLeen Wehbeh
Leen Wehbeh
SDSunita Dia
Sunita Dia
PPPrathyusha Pagadala
Prathyusha Pagadala
KBKenneth Burman
Kenneth Burman
Cristiane J Gomes-Lima, Sanjita Chittimoju, Leen Wehbeh, Sunita Dia, Prathyusha Pagadala, Mohammad Al-Jundi, Sakshi Jhawar, Eshetu Tefera, Mihriye Mete, Joanna